Reclassification of Mongolian Diffuse Gliomas According to the Revised 2016 World Health Organization Central Nervous System Tumor Classification
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The 2016 World Health Organization (WHO) classification of central nervous system (CNS) tumors has been modified to incorporate the IDH mutation and 1p/19q co-deletion in the diagnosis of diffuse gliomas. In this study, we aimed to evaluate the feasibility and prognostic significance of the revised 2016 WHO classification of CNS tumors in Mongolian patients with diffuse gliomas. Methods: A total of 124 cases of diffuse gliomas were collected, and tissue microarray blocks were made. IDH1 mutation was tested using immunohistochemistry, and 1p/19q co-deletion status was examined using fluorescence in situ hybridization analysis. Results: According to the 2016 WHO classification, 124 cases of diffuse brain glioma were reclassified as follows: 10 oligodendroglioma, IDHmut and 1p/19q co-deleted; three anaplastic oligodendroglioma, IDHmut and 1p/19q co-deleted; 35 diffuse astrocytoma, IDHmut, 11 diffuse astrocytoma, IDHwt, not otherwise specified (NOS); 22 anaplastic astrocytoma, IDHmut, eight anaplastic astrocytoma, IDHwt, NOS; and 35 glioblastoma, IDHwt, NOS, respectively. The 2016 WHO classification presented better prognostic value for overall survival in patients with grade II tumors than traditional histological classification. Among patients with grade II tumors, those with oligodendroglioma IDHmut and 1p/19q co-deleted and diffuse astrocytoma IDHmut showed significantly higher survival than those with diffuse astrocytoma IDHwt, NOS (p < .01). Conclusions: Mongolian diffuse gliomas could be reclassified according to the new 2016 WHO classification. Reclassification revealed substantial changes in diagnosis of both oligodendroglial and astrocytic entities. We have confirmed that the revised 2016 WHO CNS tumor classification has prognostic significance in Mongolian patients with diffuse gliomas, especially those with grade II tumors.
Abstract
Background: The 2016 World Health Organization (WHO) classification of central nervous system (CNS) tumors has been modified to incorporate the IDH mutation and 1p/19q co-deletion in the diagnosis of diffuse gliomas. In this study, we aimed to evaluate the feasibility and prognostic significance of the revised 2016 WHO classification of CNS tumors in Mongolian patients with diffuse gliomas. Methods: A total of 124 cases of diffuse gliomas were collected, and tissue microarray blocks were made. IDH1 mutation was tested using immunohistochemistry, and 1p/19q co-deletion status was examined using fluorescence in situ hybridization analysis. Results: According to the 2016 WHO classification, 124 cases of diffuse brain glioma were reclassified as follows: 10 oligodendroglioma, IDHmut and 1p/19q co-deleted; three anaplastic oligodendroglioma, IDHmut and 1p/19q co-deleted; 35 diffuse astrocytoma, IDHmut, 11 diffuse astrocytoma, IDHwt, not otherwise specified (NOS); 22 anaplastic astrocytoma, IDHmut, eight anaplastic astrocytoma, IDHwt, NOS; and 35 glioblastoma, IDHwt, NOS, respectively. The 2016 WHO classification presented better prognostic value for overall survival in patients with grade II tumors than traditional histological classification. Among patients with grade II tumors, those with oligodendroglioma IDHmut and 1p/19q co-deleted and diffuse astrocytoma IDHmut showed significantly higher survival than those with diffuse astrocytoma IDHwt, NOS (p < .01). Conclusions: Mongolian diffuse gliomas could be reclassified according to the new 2016 WHO classification. Reclassification revealed substantial changes in diagnosis of both oligodendroglial and astrocytic entities. We have confirmed that the revised 2016 WHO CNS tumor classification has prognostic significance in Mongolian patients with diffuse gliomas, especially those with grade II tumors.
참고문헌 (25)
- Cancer Genome Atlas Research Network, "Comprehensive, integrative genomic analysis of diffuse lowergrade gliomas", N Engl J Med, 372, pp.2481~2498 (2015)
- Reuss DE, "Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities", Acta Neuropathol, 130, pp.407~417 (2015)
- Louis DN, "The 2007 WHO classification of tumours of the central nervous system", Acta Neuropathol, 114, pp.97~109 (2007)
- Hirose Y, "Subgrouping of gliomas on the basis of genetic profiles", Brain Tumor Pathol, 30, pp.203~208 (2013)
- Tabouret E, "Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort", Acta Neuropathol, 132, pp.625~634 (2016)
- David N. Louis, "International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading", Brain Pathology, 24(5), pp.429~435 (2014), Wiley[DOI]
- Louis DN, "The 2016 World Health Organization classification of tumors of the central nervous system : a summary", Acta Neuropathol, 131, pp.803~820 (2016)
- Gupta A, "A simplified overview of World Health Organization classification update of central nervous system tumors 2016", J Neurosci Rural Pract, 8, pp.629~641 (2017)
- Wesseling P, "WHO 2016 classification of gliomas", Neuropathol Appl Neurobiol, 44, pp.139~150 (2018)
- Akagi Y, "Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification", Brain Tumor Pathol, 35, pp.81~89 (2018)
- Iuchi T, "Clinical significance of the 2016WHO classification in Japanese patients with gliomas", Brain Tumor Pathol, 35, pp.71~80 (2018)
- Pisapia DJ, "The updated World Health Organization glioma classification : cellular and molecular origins of adult infiltrating gliomas", Arch Pathol Lab Med, 141, pp.1633~1645 (2017)
- Louis DN, "cIMPACT-NOW : a practical summary of diagnostic points from Round 1 updates", Brain Pathol, 29, pp.469~472 (2019)
- Boulay JL, "Loss of heterozygosity of TRIM3 in malignant gliomas", BMC Cancer, 9, pp.71~ (2009)
- Hata N, "Allelic losses of chromosome 10 in glioma tissues detected by quantitative single-strand conformation polymorphism analysis", Clin Chem, 52, pp.370~378 (2006)
- Mizoguchi M, "Molecular characteristics of glioblastoma with 1p", 19q co-deletion, 2012, pp.29, 148~153
- Balss J, "Analysis of the IDH1 codon 132 mutation in brain tumors", Acta Neuropathol, 116, pp.597~602 (2008)
- Hartmann C, "Type and frequency of IDH1and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age : a study of 1, 010 diffuse gliomas", Acta Neuropathol, 118, pp.469~474 (2009)
- Ichimura K, "IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas", Neuro Oncol, 11, pp.341~347 (2009)
- Sanson M, "Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas", J Clin Oncol, 27, pp.4150~4154 (2009)
- Mellai M, "IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors", J Neurooncol, 105, pp.345~357 (2011)
- von Deimling A, "The next generation of glioma biomarkers : MGMT methylation, BRAF fusions and IDH1 mutations", Brain Pathol, 21, pp.74~87 (2011)
- Bigner SH, "Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization", Am J Pathol, 155, pp.375~386 (1999)
- Cohen AL, "IDH1 and IDH2 mutations in gliomas", Curr Neurol Neurosci Rep, 13, pp.345~ (2013)
- Yan H, "IDH1 and IDH2 mutations in gliomas", N Engl J Med, 360, pp.765~773 (2009)